A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
Alexandra S. Zimmer(Johns Hopkins University), Jung Min Lee(Kyung Hee University), E. Hitt Nichols(Leidos (United States)), Nicole Houston(Johns Hopkins University), Cody J. Peer(National Institutes of Health), Margaret E. Gatti‐Mays(National Cancer Institute), Liang Cao(National Institutes of Health), Christina M. Annunziata(National Cancer Institute), Lekha Mikkilineni, Jane B. Trepel(National Institutes of Health), Ashley Cimino‐Mathews(Bloomberg (United States)), Stanley Lipkowitz(Center for Cancer Research), William D. Figg(National Cancer Institute), Elise C. Kohn(National Cancer Institute), Min-Jung Lee(National Institutes of Health), Rajni Sharma(Central University of Punjab)
Cited by 112
Related Papers
Targeting the dynamic HSP90 complex in cancer
|Nature reviews. Cancer|2010|1.5k
Precisely printable and biocompatible silk fibroin bioink for digital light processing 3D printing
|Nature Communications|2018|964
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
|Cancer Cell|2007|949
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817